{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:44:36Z","timestamp":1761569076883,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clgc.2019.10.003","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T13:09:46Z","timestamp":1575551386000},"page":"e145-e156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1677-8477","authenticated-orcid":false,"given":"Elena","family":"Bolzacchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziella","family":"Pinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Bert\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Verusio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Mumoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Barbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Danova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bregni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Artale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-2964","authenticated-orcid":false,"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Torchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Barzaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Suter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Ballerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Vallini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Dentali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.10.003_bib1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New insights into molecular mechanisms of sunitinib-associated side effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2019.10.003_bib2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1470-2045(09)70185-8","article-title":"Sunitinib in renal-cell carcinoma: expanded indications","volume":"10","author":"Choueiri","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.10.003_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of targeted therapy and their management in kidney cancer","volume":"59","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.10.003_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.clgc.2019.10.003_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/0284186X.2010.543696","article-title":"Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma","volume":"50","author":"Bono","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2019.10.003_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2019.10.003_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000329933","article-title":"Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines","volume":"35","author":"Szmit","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.clgc.2019.10.003_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bju.12940","article-title":"Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma","volume":"117","author":"Rautiola","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.10.003_bib9","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2007.11.5113","article-title":"Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?","volume":"25","author":"Van Heeckeren","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.10.003_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"Riesenbeck","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2019.10.003_bib11","first-page":"3177","article-title":"Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy","volume":"34","author":"Kust","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2019.10.003_bib12","first-page":"230","article-title":"Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?","volume":"28","author":"Bozkurt","year":"2016","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.clgc.2019.10.003_bib13","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients","volume":"113","author":"Donskov","year":"2015","journal-title":"Br J Cancer"},{"year":"2010","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010)","key":"10.1016\/j.clgc.2019.10.003_bib14"},{"key":"10.1016\/j.clgc.2019.10.003_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"Guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2019.10.003_bib16","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.10.003_bib17","first-page":"H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clgc.2019.10.003_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10456-004-2699-3","article-title":"Angiogenic growth factors and hypertension","volume":"7","author":"Sane","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.clgc.2019.10.003_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V79.3.634.634","article-title":"Role of c-kit ligand in the expansion of human hematopoietic progenitor cells","volume":"79","author":"Brandt","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2019.10.003_bib20","first-page":"327","article-title":"In\u00a0vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.10.003_bib21","first-page":"471","article-title":"SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2019.10.003_bib22","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A\u00a0novel tyrosinekinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2019.10.003_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.clgc.2019.10.003_bib24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2019.10.003_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clgc.2012.08.002","article-title":"Thyroid dysfunction in patients treated with sunitinib or sorafenib","volume":"10","author":"Clemons","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.10.003_bib26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/annonc\/mdr275","article-title":"Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?","volume":"23","author":"Sabatier","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.10.003_bib27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.10.003_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2019.10.003_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/5584_2018_328","article-title":"Hand-foot syndrome and progression-free survival in patients treated with sunitinib for metastatic clear cell renal cell carcinoma","volume":"1133","author":"Kucharz","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clgc.2019.10.003_bib30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.4103\/0973-1482.189247","article-title":"Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: a single center experience","volume":"14","author":"Abd Ghafar","year":"2018","journal-title":"J\u00a0Cancer Res Ther"},{"issue":"Suppl 5","key":"10.1016\/j.clgc.2019.10.003_bib31","first-page":"v58","article-title":"Escudier B1, Porta C2, Schmidinger M3, Rioux-Leclercq N4, Bex A5, Khoo V6, Gruenvald V7, Horwich A8; ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines","volume":"27","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:31Z","timestamp":1761564691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319303076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1558767319303076"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.10.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}